Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

88%

7 of 8 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 3

4(44.4%)

Phase 2

3(33.3%)

N/A

1(11.1%)

Phase 1

1(11.1%)

9Total

Phase 3(4)

Phase 2(3)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02946073Phase 3Completed

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain

Role: lead

NCT02672111Phase 3Completed

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

Role: lead

NCT02710526Phase 2Completed

Phase II Pharmacokinetics Study of CAM2038

Role: lead

NCT02658357Phase 2Completed

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

Role: lead

NCT02773576Phase 3Completed

Safety and Tolerability of Risperidone Implants

Role: lead

NCT02611752Phase 2Completed

A Multiple Dose Opioid Challenge Study

Role: lead

NCT02651584Phase 3Completed

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Role: lead

NCT02824666Phase 1Completed

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

Role: lead

NCT02896660Not ApplicableUnknown

Probuphine Innovations for Clinical Effectiveness (PRINCE)

Role: collaborator

All 9 trials loaded